PURPOSE: To determine the prevalence of insulin resistance and other risk factors for cardiovascular disease (CVD) in young adult survivors of childhood acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS: In this cross-sectional evaluation of 118 survivors of childhood ALL (median age, 23.0 years; range, 18 to 37 years), insulin resistance was estimated using the homeostasis model for assessment of insulin resistance (HOMA-IR). Sex-specific comparisons were made with a cohort of 30- to 37-year-old individuals from the same region participating in the Dallas Heart Study (DHS, N = 782). ALL survivors were stratified by treatment with and without cranial radiotherapy (CRT). RESULTS: Female ALL survivors had a significantly higher HOMA-IR (CRT, mean 4.6, 95% CI, 3.6 to 5.7; no CRT, mean 3.3, 95% CI, 2.8 to 3.8) in comparison with DHS women (mean 2.4, 95% CI, 2.2 to 2.7). Eighty percent of women treated with CRT had at least three of six CVD risk factors, and they were significantly more likely to have three or more risk factors compared with DHS women (odds ratio [OR], 5.96; 95% CI, 2.15 to 16.47). Male ALL survivors had a significantly higher HOMA-IR (CRT, mean 4.0, 95% CI, 2.8 to 5.6; no CRT, mean 3.4, 95% CI, 2.9 to 3.9) in comparison with DHS men (mean 2.3, 95% CI, 2.1 to 2.6), but were not more likely to have multiple CVD risk factors. CONCLUSION: ALL survivors had an increased prevalence of insulin resistance in comparison with a cohort of older individuals from the same community. Importantly, women treated with CRT seem to have an increased prevalence of multiple CVD risk factors, warranting close monitoring and risk-reducing strategies.
PURPOSE: To determine the prevalence of insulin resistance and other risk factors for cardiovascular disease (CVD) in young adult survivors of childhood acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS: In this cross-sectional evaluation of 118 survivors of childhood ALL (median age, 23.0 years; range, 18 to 37 years), insulin resistance was estimated using the homeostasis model for assessment of insulin resistance (HOMA-IR). Sex-specific comparisons were made with a cohort of 30- to 37-year-old individuals from the same region participating in the Dallas Heart Study (DHS, N = 782). ALL survivors were stratified by treatment with and without cranial radiotherapy (CRT). RESULTS: Female ALL survivors had a significantly higher HOMA-IR (CRT, mean 4.6, 95% CI, 3.6 to 5.7; no CRT, mean 3.3, 95% CI, 2.8 to 3.8) in comparison with DHSwomen (mean 2.4, 95% CI, 2.2 to 2.7). Eighty percent of women treated with CRT had at least three of six CVD risk factors, and they were significantly more likely to have three or more risk factors compared with DHSwomen (odds ratio [OR], 5.96; 95% CI, 2.15 to 16.47). Male ALL survivors had a significantly higher HOMA-IR (CRT, mean 4.0, 95% CI, 2.8 to 5.6; no CRT, mean 3.4, 95% CI, 2.9 to 3.9) in comparison with DHSmen (mean 2.3, 95% CI, 2.1 to 2.6), but were not more likely to have multiple CVD risk factors. CONCLUSION: ALL survivors had an increased prevalence of insulin resistance in comparison with a cohort of older individuals from the same community. Importantly, women treated with CRT seem to have an increased prevalence of multiple CVD risk factors, warranting close monitoring and risk-reducing strategies.
Authors: K C Oeffinger; G R Buchanan; D A Eshelman; M A Denke; T C Andrews; J A Germak; G E Tomlinson; L E Snell; B M Foster Journal: J Pediatr Hematol Oncol Date: 2001-10 Impact factor: 1.289
Authors: Ching-Hon Pui; Cheng Cheng; Wing Leung; Shesh N Rai; Gaston K Rivera; John T Sandlund; Raul C Ribeiro; Mary V Relling; Larry E Kun; William E Evans; Melissa M Hudson Journal: N Engl J Med Date: 2003-08-14 Impact factor: 91.245
Authors: Ronald G Victor; Robert W Haley; DuWayne L Willett; Ronald M Peshock; Patrice C Vaeth; David Leonard; Mujeeb Basit; Richard S Cooper; Vincent G Iannacchione; Wendy A Visscher; Jennifer M Staab; Helen H Hobbs Journal: Am J Cardiol Date: 2004-06-15 Impact factor: 2.778
Authors: Ram Weiss; James Dziura; Tania S Burgert; William V Tamborlane; Sara E Taksali; Catherine W Yeckel; Karin Allen; Melinda Lopes; Mary Savoye; John Morrison; Robert S Sherwin; Sonia Caprio Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245
Authors: Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Yutaka Yasui; Thomas Fears; Marilyn Stovall; Terry A Vik; Peter D Inskip; Leslie L Robison Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 50.717
Authors: David C Landy; Tracie L Miller; Gabriela Lopez-Mitnik; Stuart R Lipsitz; Andrea S Hinkle; Louis S Constine; Carol A French; Amy M K Rovitelli; M Jacob Adams; Steven E Lipshultz Journal: Am Heart J Date: 2012-02 Impact factor: 4.749
Authors: Smita Bhatia; Saro H Armenian; Gregory T Armstrong; Eline van Dulmen-den Broeder; Michael M Hawkins; Leontien C M Kremer; Claudia E Kuehni; Jørgen H Olsen; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Emily S Tonorezos; Melissa M Hudson; Angela B Edgar; Leontien C Kremer; Charles A Sklar; W Hamish B Wallace; Kevin C Oeffinger Journal: Lancet Diabetes Endocrinol Date: 2015-04-12 Impact factor: 32.069
Authors: Emily K Browne; Yinmei Zhou; Wassim Chemaitilly; John C Panetta; Kirsten K Ness; Sue C Kaste; Cheng Cheng; Mary V Relling; Ching-Hon Pui; Hiroto Inaba Journal: Cancer Date: 2018-10-25 Impact factor: 6.860
Authors: Chantel Cacciotti; Muhammad Ali; Ute Bartels; Jonathan D Wasserman; Erilda Kapllani; Joerg Krueger; Eric Bouffet; Tal Schechter Journal: Childs Nerv Syst Date: 2020-11-18 Impact factor: 1.475